BAOHUA MARK HUANG
Pharmacy in Ann Arbor, MI
License number
Michigan 5304000865
Issued Date
Mar 29, 2011
Expiration Date
Jun 30, 2012
Category
Pharmacy
Type
CS - Research Lab
Address
Address
Ann Arbor, MI 48109
Personal information
See more information about BAOHUA MARK HUANG at radaris.comName
Address
Phone
1602 Gaylord St, Mount Pleasant, MI 48858
1739 Timber Trl, Ann Arbor, MI 48103
281 Rolling Meadows Dr, Ann Arbor, MI 48103
301 Broomfield St, Mount Pleasant, MI 48858
Professional information
See more information about BAOHUA MARK HUANG at trustoria.com
Dendrimer Based Modular Platforms
Dendrimer Based Modular Platforms
US Patent:
2010015, Jun 24, 2010
Filed:
Dec 22, 2009
Appl. No.:
12/645081
Inventors:
Mark M. Banaszak Holl - Ann Arbor MI, US
Xue-min Cheng - Ann Arbor MI, US
Baohua Huang - Ann Arbor MI, US
Douglas G. Mullen - Ann Arbor MI, US
Thommey Thomas - Dexter MI, US
Xue-min Cheng - Ann Arbor MI, US
Baohua Huang - Ann Arbor MI, US
Douglas G. Mullen - Ann Arbor MI, US
Thommey Thomas - Dexter MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 31/74, C08G 69/00
US Classification:
424 7808, 528310
Abstract:
The present invention relates to novel therapeutic and diagnostic dendrimer based modular platforms (e.g., drug delivery platforms). In particular, the dendrimer based modular platforms are configured such that two or more dendrimers (e.g., PAMAM dendrimers) are coupled together (e.g., via a cycloaddition reaction) wherein each of the coupled dendrimers is functionalized (e.g., functionalized for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy). In some embodiments, the present invention provides dendrimer based modular platforms having coupled dendrimers (e.g., two or more coupled dendrimers) wherein each dendrimer is conjugated to one or more functional groups (e.g., therapeutic agent, imaging agent, targeting agent, triggering agent) (e.g., for specific targeting and/or therapeutic use of the dendrimer based modular platform). In some embodiments, the functional groups are conjugated to the dendrimers via a linker and/or a triggering agent. In addition, the present invention is directed to methods of synthesizing dendrimer based modular platforms, compositions comprising the dendrimer based modular platforms, as well as systems and methods utilizing the dendrimer based modular platforms (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.)).
Pro-Drug Complexes And Related Methods Of Use
Pro-Drug Complexes And Related Methods Of Use
US Patent:
2012017, Jul 5, 2012
Filed:
Jun 30, 2010
Appl. No.:
13/378178
Inventors:
Baohua M. Huang - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Thommey P. Thomas - Dexter MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 31/4745, C07K 14/71, C07K 17/02, C12N 5/09, A61K 38/18, A61K 39/44, A61K 38/12, A61P 35/00, C07D 491/22, C07K 7/64
US Classification:
4241811, 546 48, 530399, 5303917, 5303919, 530321, 514283, 514 81, 514 96, 514 193, 435375, 435366
Abstract:
The present invention provides methods, compositions and applications for efficient, site-specific drug delivery using pro-drug complexes comprising therapeutic agents and one or more functional groups (e.g., imaging agents, targeting agents, and trigger agents). In particular, the present invention relates to pro-drug complexes comprising one or more functional groups conjugated with a therapeutic agent (e.g., a chemotherapeutic agent), methods of synthesizing the same, as well as systems and methods utilizing the therapeutic and diagnostic compositions (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.)).
Dendrimer Conjugates
Dendrimer Conjugates
US Patent:
2010016, Jun 24, 2010
Filed:
Sep 30, 2009
Appl. No.:
12/570977
Inventors:
Xue-min Cheng - Ann Arbor MI, US
Abraham F.L. Van Der Spek - Ann Arbor MI, US
Baohua Mark Huang - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Abraham F.L. Van Der Spek - Ann Arbor MI, US
Baohua Mark Huang - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 31/5513, C07D 489/02, A61K 31/485, C07D 243/24, C07D 413/06, A61K 31/5377
US Classification:
514221, 546 46, 514282, 540507, 544141, 5142372
Abstract:
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
Divergent Synthesis Of Looped Poly(Ester)-And Poly(Ether)-Substituted Dendrons And Dendrimers
Divergent Synthesis Of Looped Poly(Ester)-And Poly(Ether)-Substituted Dendrons And Dendrimers
US Patent:
2010008, Apr 8, 2010
Filed:
Dec 28, 2007
Appl. No.:
12/448513
Inventors:
Donald A. Tomalia - Midland MI, US
Douglas R. Swanson - Mt. Pleasant MI, US
Baohua Huang - Ann Arbor MI, US
Veera Reddy Pulgam - Mt. Pleasant MI, US
Douglas R. Swanson - Mt. Pleasant MI, US
Baohua Huang - Ann Arbor MI, US
Veera Reddy Pulgam - Mt. Pleasant MI, US
Assignee:
Dendritic Nanotechnologies, Inc. - Mt. Pleasant MI
International Classification:
A61K 49/00, C07D 487/00, C07D 491/00, A61K 31/395, C07D 245/00, A61K 31/495, A61K 31/16, G01N 33/566
US Classification:
424 91, 540469, 514450, 540467, 540460, 564135, 514250, 514616, 436 94
Abstract:
The present invention describes a process for preparing new looped dendrimer and dendron compounds by controlling the molar amount of branch cell reagent monomer that is combined with various cores bearing core-XR functionalities (e.g., primary, or secondary amines, thiol, or epoxy functionalities). These looped, macrocyclic structures are more robust to various conditions, with greater resistance to acid/base hydrolysis. Alternatively, the looped, macrocyclic structure may offer new orientations that would qualify it as a better chelation ligand for metals, and other similar uses.
Dendrimer Conjugates
Dendrimer Conjugates
US Patent:
2009028, Nov 19, 2009
Filed:
Mar 12, 2009
Appl. No.:
12/403179
Inventors:
Xue-min Cheng - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Baohua Mark Huang - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Baohua Mark Huang - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C07D 305/08
US Classification:
549510
Abstract:
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
Dendrimer Conjugates
Dendrimer Conjugates
US Patent:
8445528, May 21, 2013
Filed:
Jul 12, 2012
Appl. No.:
13/547929
Inventors:
Xue-min Cheng - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Baohua Mark Huang - Ann Arbor MI, US
Thommey P. Thomas - Dexter MI, US
Baohua Mark Huang - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 31/403, A61K 31/485, C07D 209/12, C07D 471/04
US Classification:
514412, 514282, 548452, 546 45, 977754, 424400, 424486
Abstract:
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e. g. , in diagnostic and/or therapeutic settings (e. g. , for the delivery of therapeutics, imaging, and/or targeting agents (e. g. , in disease (e. g. , cancer) diagnosis and/or therapy, pain therapy, etc. )). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
Dendrimer Compositions And Methods Of Synthesis
Dendrimer Compositions And Methods Of Synthesis
US Patent:
2012025, Oct 11, 2012
Filed:
Oct 7, 2010
Appl. No.:
13/502004
Inventors:
Baohua Huang - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
C07K 17/02, C07D 311/82, C07C 57/12, C07K 1/04, C07H 1/00, C07H 21/04, C07D 219/08, B82Y 15/00
US Classification:
5303913, 536 231, 530350, 5303911, 530395, 530394, 549223, 546107, 554224, 530409, 536 253, 530405, 5303917, 977700, 977810, 977774, 977746, 977811
Abstract:
The present invention relates to novel dendrimer compounds and methods of synthesizing the same. In particular, the present invention is directed to novel polyamidoamine (PAMAM) dendrimers, novel dendrimer branching units, methods for synthesizing such novel PAMAM dendrimers and functionalized dendrimers, as well as systems and methods utilizing the dendrimers (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease diagnosis and/or therapy, etc.))).